Affymetrix introduces cost-effective, high-throughput Axiom 384HT format for genotyping Affymetrix, Inc. ‘This latest addition to the Axiom genotyping system uniquely addresses a development in both the human and agrigenomics areas of research using population-optimized or application-focused content in conjunction with low operating price,’ stated Andy Last, Executive Vice President of Genetic Evaluation and Clinical Applications Business Device at Affymetrix. ‘The new format raises throughput per system by fourfold, meeting the expanding demands of targeted genotyping on very large amounts of samples at a significantly reduced cost. Custom arrays could be delivered and manufactured to clients in less than four to six weeks.The Ministry also mentioned that the rest of the 4 SARS patients were still hospitalized in Beijing. 1 individual is in a serious condition but the additional 3 are on the path to recovery. Non-e of the 747 initial primary contacts have shown any unusual symptoms and all have been removed from observation.
Advanced pancreatic cancer individuals now have access to new FDA-approved drug, Onivyde Patients with advanced pancreatic cancer now have access to the new FDA approved drug, Onivyde, that produced significant general survival rates in an international clinical research conducted partly by researchers at HonorHealth Analysis Institute and the Translational Genomics Study Institute .